BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38244585)

  • 1.
    Wang FM; Xu LQ; Zhang ZC; Guo Q; Du ZP; Lei Y; Han X; Wu CY; Zhao F; Chen JL
    Aging (Albany NY); 2024 Jan; 16(2):1605-1619. PubMed ID: 38244585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and immunological potential of PPM1G in lung adenocarcinoma.
    Yin R; Qu L; Wang Z; Tang J; Gu H; Wang X; Yang D; Du P; Dong M
    Mol Med Rep; 2023 Aug; 28(2):. PubMed ID: 37387407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of BCCIP predicts an unfavorable prognosis and promotes the proliferation and migration of lung adenocarcinoma.
    Shi J; Lv X; Li W; Ming Z; Zeng L; Yuan J; Chen Y; Liu B; Yang S
    Thorac Cancer; 2021 Sep; 12(17):2324-2338. PubMed ID: 34297484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated ADAR expression is significantly linked to shorter overall survival and immune infiltration in patients with lung adenocarcinoma.
    Hu S; Wang F; Yang J; Xu X
    Math Biosci Eng; 2023 Sep; 20(10):18063-18082. PubMed ID: 38052548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) correlates with poor prognosis and immune infiltration in lung adenocarcinoma.
    Zhuo X; Chen L; Lai Z; Liu J; Li S; Hu A; Lin Y
    Bioengineered; 2021 Dec; 12(1):8336-8346. PubMed ID: 34592886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Expression of
    Chen Y; Zhou M; Gu X; Wang L; Wang C
    Dis Markers; 2022; 2022():8789515. PubMed ID: 35855850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of CDT1 as a prognostic marker in human lung adenocarcinoma using bioinformatics approaches.
    Jiang J; Zhang Y; Wang J; Yang X; Ren X; Huang H; Wang J; Lu J; Zhong Y; Lin Z; Lin X; Jia Y; Lin S
    PeerJ; 2023; 11():e16166. PubMed ID: 37790630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of
    Bian T; Zhang W; Wang F; Chu X; Pan X; Ruan J; Yu S; Liu L; Sun H; Qiu H; Li Y; Tang J; Zhao X; Zhang H
    Comb Chem High Throughput Screen; 2023; 26(14):2452-2468. PubMed ID: 37038295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma.
    Zhang S; Lu Y; Qi L; Wang H; Wang Z; Cai Z
    Biomed Res Int; 2020; 2020():8571932. PubMed ID: 32904605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J
    BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
    Tang X; Zhou H; Liu Y
    Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
    Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
    Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mutational Signatures Analysis of Micropapillary Components and Exploration of ZNF469 Gene in Early-stage Lung Adenocarcinoma with Ground-glass Opacities].
    Xu Y; Sun Q; Wang S; Zhu H; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Chen P; Yuan F; Yu X; Ji J; Li Z; Zhu P; Sun Y; Liu T; Yin R; Xu L
    Zhongguo Fei Ai Za Zhi; 2024 Jan; 26(12):889-900. PubMed ID: 38151328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
    Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
    Front Immunol; 2021; 12():724741. PubMed ID: 34335635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression and diagnostic significance of INTS7 in lung adenocarcinoma and its effects on tumor microenvironment.
    Li X; Yao Y; Qian J; Jin G; Zeng G; Zhao H
    Int Immunopharmacol; 2021 Dec; 101(Pt B):108346. PubMed ID: 34781123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HMMR associates with immune infiltrates and acts as a prognostic biomaker in lung adenocarcinoma.
    Ma X; Xie M; Xue Z; Yao J; Wang Y; Xue X; Wang J
    Comput Biol Med; 2022 Dec; 151(Pt A):106213. PubMed ID: 36306573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of TTC21A in lung adenocarcinoma infers favorable prognosis and high immune infiltrating level.
    Wang W; Ren S; Wang Z; Zhang C; Huang J
    Int Immunopharmacol; 2020 Jan; 78():106077. PubMed ID: 31812070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-DPA1 overexpression inhibits cancer progression, reduces resistance to cisplatin, and correlates with increased immune infiltration in lung adenocarcinoma.
    Shi K; Li QY; Zhang YQ; Huang H; Ding DX; Luo WM; Zhang J; Guo Q
    Aging (Albany NY); 2023 Oct; 15(20):11067-11091. PubMed ID: 37899135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and Immune Characteristics for Lung Adenocarcinoma Patients With ERLIN2 Overexpression.
    Liu Y; Xie P; Jiang D; Liu J; Zhang J; Bian T; Shi J
    Front Immunol; 2020; 11():568440. PubMed ID: 33424830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research.
    Wu L; Zhong Y; Yu X; Wu D; Xu P; Lv L; Ruan X; Liu Q; Feng Y; Liu J; Li X
    Anticancer Drugs; 2022 Oct; 33(9):943-959. PubMed ID: 35946526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.